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Abstract Mutations in the ALDOB gene impair the
activity of the hepatic aldolase B enzyme, causing heredi-
tary fructose intolerance (HFI), an inherited autosomic
recessive disease of carbohydrate metabolism, that can
result in hypoglycemia, liver and kidney failure, coma, and
death. Noninvasive diagnosis is possible by identifying
mutant ALDOB alleles in suspected patients. We report the
genetic characterization of a cohort of 18 HFI Caucasian
patients, based on PCR-sequencing and Multiplex Ligation-
dependent Probe Amplification (MLPA), with the identifi-
cation of two novel genetic lesions: a small duplication
c.940_941dupT (p.Trp314fsX22) and a large deletion
encompassing the promoter region and exon 1. MLPA
and long range-PCR (LR-PCR) also identified the recently
reported g.7840_14288del6448 allele with a surprisingly
high frequency (11%) within our patients’ cohort. The
most common p.Ala150Pro (44%), p.Ala175Asp (19%),
p.Asn335Lys (8%), and/or the known c.360-363del4 (5%),
p.Tyr204X (2.8%), IVS6 2A>G (2.8%) mutant alleles
were identified in 14 patients at a homozygous or
compound-heterozygous level. The integration of PCR-
sequencing analysis with exon-dosage tools [MLPA and
quantitative fluorescent multiplex-PCR (QFM-PCR)] led to
the full genotyping of patients within our cohort and to
the identification of the new deletion encompassing the
promoter region and exon 1.
Introduction
Hereditary fructose intolerance (HFI) (EC 4.1.2.13; OMIM
ID: 229600) is a rare (1 in 20,000 births, Steinman et al.
2001) recessive inherited disorder of carbohydrate metabo-
lism, caused by catalytic deficiency of the aldolase B
enzyme (ALDOB; EC 4.1.2.13). The ALDOB enzyme
plays a key role in glycolysis and gluconeogenesis and, in
mammals, is preferentially expressed in the liver. HFI
patients manifest hypoglycemia, lactic acidosis, and gastro-
intestinal symptoms, such as severe abdominal pain and
recurrent vomiting after consuming fructose-containing
foods. HFI usually presents in infancy at the time of
weaning, when fructose is added to the diet. Persistent
ingestion of fructose and related sugars (such as sucrose
and sorbitol) can lead to severe liver and kidney damage,
seizures, coma, and risk of death (Alì et al. 1993). Patients
who achieve adulthood develop a natural aversion to fruit
and sweets (Alì et al. 1998; Steinman et al. 2001). Early
diagnosis is essential, as patients can live a symptom-free
life by avoiding sweet foods containing fructose, including
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certain pharmacological preparations such as syrups, which
contain problematic sugars.
Noninvasive diagnosis is possible using genomic
DNA sequencing analysis by the detection of genetic
lesions in the ALDOB gene (Alì et al. 1998), mapping
on chromosome 9q. ALDOB consists of nine exons
encoding a polypeptide containing 364 amino acids (Tolan
and Penhoet 1986). At present, 56 ALDOB disease-
causing mutations have been identified (Human Gene
Mutation Database (HGMD), http://www.hgmd.cf.ac.uk/ac/
index.php), but the severity of the disease appears not
to be dependent upon the nature of the ALDOB
mutation (Davit-Spraul et al. 2008). The mutated
p.Ala150Pro allele (Cross et al. 1988) is the most frequent
(Alì et al. 1998) and the frequency of heterozygous
carriers has been estimated to be 1.32  0.49% in the
United Kingdom (James et al. 1996). p.Ala175Asp
(Cross et al. 1990a) and p.Asn335Lys (Cross et al. 1990b)
are also frequent ALDOB mutations. Together with the
p.Ala150Pro, they account for about 72–76% of HFI
mutated alleles worldwide (Santer et al. 2005; Tolan
1995; Cross et al. 1990a, b). Population screening has
demonstrated that HFI patients are very frequently
(94%) heterozygous for at least one of the three common
mutations p.Ala150Pro, p.Ala175Asp, and p.Asn335Lys
(Santer et al. 2005). The occurrence of these three genotypes
in the same family with recurrent HFI has also been reported
(Caciotti et al. 2008). Other population studies have
estimated high frequencies of the p.Ala150Pro (50%) and
p.Ala175Asp (30%) mutations in Italy (Santamaria et al.
1993; Sebastio et al. 1991), and it has been estimated that
seven mutations account for 95% of HFI alleles in Italian
patients (Esposito et al. 2004).
Herein we report two new ALDOB genetic lesions and
the successful use of multiplex ligation-dependent probe
amplification (MLPA) in the molecular diagnostic of HFI.
We also report the allele frequencies of ALDOB mutations
that we detected in 18 newly diagnosed HFI patients.
Materials and Methods
Patients
We examined a cohort of 18 Caucasian patients with pheno-
typic manifestations of the HFI clinical spectrum (Table 1).
Their parents were also evaluated in order to confirm the
heterozygous carrier status. Informed consent was obtained
from all patients in accordance with local ethics committee
recommendations.
Table 1 HFI patients’ data and clinical manifestations
Patient Pt1 Pt2 Pt3 Pt3’s brother Pt4 Pt5
Age at diagnosis 7 years 2 years 36 years 46 years 3 years and
9 months
6 months
(weaning)
Age at present 11 years 30 years 37 years 47 years 6 years 1 year and
8 months
Origin Albania Italy Italy Italy Italy Italy
Growth Normal Normal Lower limit of
normal (tenth
percentile)
Lower limit of
normal (tenth
percentile)
Normal Normal
Age of presentation
and symptomsa
5 months,
aversion to
fruit and
sugar
6 months,
aversion to
fruit and
sugar
Aversion to fruit
and sugar
Aversion to fruit
and sugar
Aversion to
fruit and
sugar,
hypoglycemia
6 months, aversion
to fruit and sugar,
hypoglycemia
Gastrointestinal
abnormalities
Diarrhea Vomiting Vomiting, diarrhea Vomiting – Vomiting after
fructose ingestion
Laboratory findings Hyp-transb Hyp-transb Hyp-transb No Hyp-transb Hyp-transb, slightly
increased CK
levels
Aversion to any
source of fructose
Yes Yes Yes Yes Yes Yes
Therapy Diet Diet Diet Diet Diet Diet
Other Hepatic
steatosis
Hepatic
steatosis
Crohn's disease at
34 years, hepatic
steatosis
Osteoporosis,
hepatic steatosis
Hepatic
steatosis
Hepatic steatosis
aWhen presenting, symptoms have followed sweets and/or fruit ingestion
b Hypertransaminasemia
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Analysis of Genomic DNA
Genomic DNA was isolated using the EZ1 DNA Blood
350 ml Kit (QIAGEN, Hilden, Germany). The three
ALDOB fragments which encompass exons 5, 8, and 9
including the p.Ala150Pro, p.Ala175Asp, and p.Asn335Lys
frequent mutations were amplified and sequenced. In
patients without common mutations or with only one
mutant allele, molecular analysis was extended to the entire
coding region. Oligonucleotides and PCR conditions are
available on request.
Nucleotide positions were named on the basis of
ALDOB reference sequence NG_012387.1 and HGVS
standard nomenclature (http://www.hgvs.org/mutnomen).
p.Ala150Pro, p.Ala175Asp, p.Asn335Lys, and p.Tyr204X
correspond to mutations p.Ala149Pro, p.Ala174Asp,
p.Asn334Lys, and p.Tyr203X, respectively, in HGMD
nomenclature.
Multiplex Ligation-Dependent Probe Amplification
Analysis
MLPA was carried out using the SALSA MLPA KIT P255
ALDOB (MRC Holland, Amsterdam, The Netherlands),
which contains 16 control probes, and 11 probes specific to
the ALDOB gene, 1 probe for each exon and 2 probes that
reveal the p.Ala150Pro and p.Ala174Asp mutations. Reac-
tions were carried out as reported (www.mlpa.com) and
confirmed at least in duplicate. Electrophoresis was
performed with an ABI 3130XL sequencer (Applied
Biosystems, Carlsbad, CA). For each sample, each peak
area was normalized by dividing it by the combined area of
all peaks in that sample. Normalized areas were then
divided by the average normalized peak area from at least
three normal controls. Values obtained indicate the allele
copy numbers compared with normal controls (Hogervorst
et al. 2003). Values of 0.7–1.3 were assumed as normal and
<0.7 as deletions. False-positives were excluded by DNA
sequence analysis of probe hybridization sites.
Multiplex-PCR Analysis to Confirm Homozygous Large
Deletion
Combinations of PCR-fragments: exons 2 + 8; exons
3 + 7; exons 4 + 8; exons 5 + 8; and exons 6 + 8 were
successfully assayed. Products were checked by agarose gel
electrophoresis using 2% Agarose Low Melting (Eurobio,
France) + 1% Standard Agarose (AB Analitica, Italy).
Breakpoint Determination
The breakpoint junctions of the large gene rearrange-
ment encompassing exons 2–6 were amplified by long
range-PCR (LR-PCR) using the Platinum Taq, DNA
polymerase High Fidelity (Invitrogen, USA) and directly
sequenced. PCR and sequencing conditions are available on
request.
Quantitative Fluorescent Multiplex-PCR of Exons 1 and 2
ALDOB exons 1 and 2 were amplified in one multiplex
reaction, including the internal quantitative control FECH8
(Dobrovolny et al. 2011). ALDOB exon 1 produces a
fragment of 249 bp, ALDOB exon 2 of 319 bp, and FECH8
of 235 bp. PCR and sequencing conditions are available
on request. PCR products were run on an ABI 3130XL
sequencer (Applied Biosystems, Carlsbad, CA). For each
sample, the peak areas of each ALDOB exon were
normalized by dividing them by the peak area of the
internal control FECH8. Normalized areas were then
divided by the average normalized peak area from at least
three normal controls. Values obtained were interpreted as
described for MLPA. Validation of the assay was performed
by analyzing 11 control DNAs and the genomic DNAs of
the homozygous and heterozygous known ALDOB large
deletion g.7840_14288del6448 that involves exon 2.
Results
ALDOB Mutated Alleles Identified in Our HFI Cohort
and Their Distribution
The three most common mutations p.Ala150Pro,
p.Ala175Asp, and p.Asn335Lys had a prevalence of 44,
19, and 8%, respectively, in agreement with the literature (Alì
et al. 1998; Sebastio et al. 1991). Other known mutated alleles
were found with minor frequencies, 5% for c. 360_363del4
(Dazzo and Tolan 1990), 2.8% for p.Tyr204X (Alì et al.
1993), and 2.8% for IVS6 2A>G (Esposito et al. 2004).
Five remarkable cases led to the identification of two
new mutations (c.940_941dupT and a large deletion
encompassing the promoter region and exon 1) and of
the recently reported g.7840_14288del6448 large deletion
(Esposito et al. 2010), which was found at a
high frequency in our cohort (11%). Allele combinations
identified in our cohort and their relative frequencies are
reported in Table 2.
The New Mutated Allele c.940_941dupT
Molecular analysis of an Albanian proband (Pt1, Table 1)
identified, at a heterozygous level, the new mutation
c.940_941dupT in exon 8, combined with the recurrent
mutation p.Ala175Asp. In silico analysis revealed that this
new mutation causes a frameshift leading to the lesion
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p.Trp314fsX22 at the protein level. Molecular analysis of the
patient’s relatives identified heterozygous c.940_941dupT
in his father and heterozygous p.Ala175Asp in his mother
and sister.
A New Large Deletion Encompassing the Promoter
Region and Exon 1
The Italian patient Pt2 (Table 1) had previously received
biochemical diagnosis of HFI after liver biopsy. DNA
sequencing of the entire ALDOB gene coding sequence and
of the fragment containing the promoter region and exon 1
(Coffee and Tolan 2010) only revealed the p.Ala150Pro
mutation at a heterozygous status. MLPA analysis identified
a deletion involving the region containing the promoter and
exon 1 at the heterozygous status (Fig. 1b, lane 1). Direct
sequencing and MLPA analysis of the patient’s daughter
led to the identification of the heterozygous p.Ala150Pro
(Fig. 1b, lane 2), indicating that the two mutations were in
trans in the genome of the proband. Since the p.Ala150Pro
mutation is very frequent, we excluded the possibility that
the carrier status of the daughter was inherited from the
mother by also analyzing her mother at the ALDOB
molecular level. Amplification of the ALDOB exon 1 and
the promoter region with the specific primers (Coffee and
Tolan 2010) did not identify genetic lesions in the proband,
excluding an interference by an SNP within the annealing
region of specific MLPA Probes. LR-PCR amplification
with two different forward primers annealing one upstream
and one in the promoter region and a reverse primer
annealing in intron 2 from patient’s DNA did not allow the
determination of the exact breakpoint because the resulting
amplicon was not different from the controls (data not
shown). To confirm this new ALDOB gene rearrangement,
we developed a specific quantitative fluorescent multiplex-
PCR (QFM-PCR) assay for the dosage of ALDOB exons 1
and 2. Data obtained confirmed the MLPA data (Table 3).
Homozygous g.7840_14288del6448 Large Deletion
Molecular analysis of an Italian proband (Pt3, Table 1)
revealed the large homozygous deletion g.7840_14288del6448
spanning exons 2–6, then confirmed by multiplex PCRs (data
not shown). Molecular analysis of the patient’s brother, who
also shows classic HFI symptoms (Table 1), identified
the same ALDOB genotype. MLPA analysis, performed on
the DNAs of the proband, his brother and their parents,
confirmed the homozygous deletion in the brother and
showed the heterozygous level of the consanguineous
parents (Fig. 1c). Since MLPA indicated that exon 1 was
not involved, LR-PCR and sequencing analysis identified
the g.7840_14288del6448 deletion. LR-PCR amplification
produced an amplicon of 3,915 bp corresponding to the
mutated allele, which is easily distinguishable from the WT
of 10,364 bp, thus confirming the heterozygous status of the
patient’s parents.
Heterozygous g.7840_14288del6448 Large Deletion
Molecular analysis of a fourth Italian family (proband Pt4,
Table 1) identified the p.Ala175Asp mutation that was
seemingly at a homozygous level. This finding, however,
was not confirmed by molecular analysis of the proband’s
parents’ DNA. p.Ala175Asp was carried only by the father
and was absent in the mother. MLPA and LR-PCR analysis
revealed the g.7840_14288del6448 large deletion in the
DNAs of the proband and her mother (Fig. 1d). An
analogous condition was found in a fifth Italian family
(Pt5, Table 1) where molecular analysis of the proband
revealed the apparently homozygous p.Ala150Pro, which
was not confirmed by analysis of parents’ DNA. LR-PCR
amplification and sequencing identified the heterozygous
g.7840_14288del6448 in the DNAs of the proband and his
father.
Discussion
Molecular analysis of the ALDOB gene sequence is the
least invasive diagnostic tool available for rapid confirma-
tion of HFI in suspected patients. From a large cohort of
patients suspected of HFI, we found 18 to be carrying
different genotypes. Only 2 of 18 patients didn't carry
any common allele. However, only 10/18 (55%) carried
combinations of the three common mutations detectable
Table 2 ALDOB allele combinations identified in our cohort
(N ¼ 18)
Allele combinations Number
of patients
Frequency
(%)
p.Ala150Pro/p.Ala150Pro 5 28
p.Ala175Asp/p.Ala175Asp 2 11
c.360_363del4/p.Ala150Pro 2 11
p.Ala150Pro/p.Ala175Asp 1 5
p.Ala150Pro/p.Asn335Lys 1 5
p.Asn335Lys/p.Asn335Lys 1 5
p.Thr204X/IVS6 2A>G 1 5
Remarkable cases
c.940_941dupT/p.Ala175Asp 1 5
delEx1/p.Ala150Pro 1 5
g.7840_14288del6448/
g.7840_14288del6448
1 5
g.7840_14288del6448/p.Ala175Asp 1 5
g.7840_14288del6448/p.Ala150Pro 1 5
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with the routinely sequence analysis, while 8/18 (45%)
carried, at least, one not common allele. Concerning the last
eight patients the sequencing analysis was extended to the
entire coding region of ALDOB gene of all of them. Such
approach led to the diagnosis in 4 of them (4/18; 22%),
while in the other 4 (22%) the diagnosis was made by
integration of molecular analysis with MLPA and/or QF-
PCR and/or LR-PCR. These methods have also confirmed
their parents’ carrier status.
We identified a new mutation consisting of a duplication
of a T in exon 8 (c.940_941dupT) that alters the ALDOB
coding region leading to the p.Trp314fsX22 protein
alteration. It was combined with the p.Ala175Asp in an
Table 3 QFM-PCR results
Patient Fluorescence ratiosa
Exon 1 Exon 2
Pt2 0.54 1.12
Pt2’s daughter 1.19 1.16
Pt3 1.11 0
Pt3’s father 1.14 0.55
Pt3’s mother 1.12 0.53
a Fluorescence ratios are calculated as indicated in the “Materials and
Methods” section and are the average of two experiments
a
b Lane 1
Lane 2
c
d
Lane 1
Lane 2
Ex 3 Ex 7 Ex 1 Ex 9 Exs 4, 5 and 6 Ex 2 Ex 8
0,56
0,65 0,46
0,53
0,5 0,5
0,67 0,59
0,66
0,65 0,63
Fig. 1 Detection of ALDOB alterations by MLPA. x-axis: fragment
size; y-axis: fluorescence intensity. Probe mix contains 22 probes and
9 of them recognize the ALDOB exons. Two probes are specific to the
common mutations p.Ala150Pro (indicated by the triangle) and
p.Ala175Asp (indicated by the star). These probes only generate a
signal for samples containing such mutations. (a) Control sample. (b)
Lane 1 represents Pt2 profile. The arrow indicates a decreased peak
area, corresponding to the heterozygous deletion of exon 1. Pt2’s
daughter (lane 2) inherited the p.Ala150Pro allele. (c) Lane 1
illustrates the Pt3 homozygous deletion of exons 2–6 as the
corresponding peaks are absent. (c) Lane 2 and (d) represent the
profiles of Pt3’s father and Pt4 that show heterozygous deletion of
exons 2–6. Normalized relative peak area ratios that indicate deletions
are shown
JIMD Reports 35
Albanian family in which recessive inheritance was
confirmed by molecular analysis of the patient’s parents.
Molecular analysis also revealed a high prevalence,
wi th in our cohor t , o f the recen t ly repo r t ed
g.7840_14288del6448 ALDOB allele, which carries a large
deletion spanning exons 2–6. The incidence of this new
emerging allele in our patient cohort (11%) was higher than
that of the common p.Asn335Lys mutation (8%). As
previously reported (Esposito et al. 2010), we also found
such deletion in patients with Italian origin, thus a founder
effect cannot be excluded. However, it is important to
screen for this allele in patients with apparently homozy-
gous ALDOB mutations in exons 2–6, when one parent
does not carry the expected mutation, in cases where
parents’ DNAs are not available for analysis and in
heterozygous HFI patients for whom the second mutation
has not been identified.
We used MLPA to investigate ALDOB gene rearrange-
ments and it was proved here to be very efficient in detecting
the g.7840_14288del6448, also at a heterozygous level.
MLPA analysis allowed us to complete the genetic analysis
in Patient 2 in whom PCR-sequencing analysis had revealed
only the p.Ala150Pro mutation at a heterozygous level. The
second mutated allele consists of a new ALDOB deletion that
involves the promoter region and exon 1. The deletion was
confirmed by specific QFM-PCR assay for the dosage of
ALDOB exons 1 and 2 that we developed and validated
successfully on the DNAs of the homozygous and heterozy-
gous large deletion, g.7840_14288del6448. ALDOB exon 1
is a noncoding exon that is supposed to be involved in the
regulation of ALDOB mRNA translation (Coffee and Tolan
2010) and mutations in this region are reported as causing
HFI (Coffee and Tolan 2010). Thus, ALDOB gene expres-
sion in our patient could be altered by this mutation both at
the transcription-regulation level and at the protein level.
Our data indicate the importance of extending sequence
analysis to the entire coding sequence and intron/exon
boundaries of the ALDOB gene of suspected HFI patients,
in accordance with recent reports (Esposito et al. 2010,
Coffee and Tolan 2010). The heterozygous status or the
mutation negative status for the most common mutations do
not exclude the affected status as such patients should be
further investigated at the molecular level. To this purpose,
PCR-sequencing analysis should be extended to the entire
coding sequence. Moreover, the ALDOB MLPA test
improves detection rates.
This report demonstrates the importance of screening the
ALDOB gene of suspected patients, especially infants, since
a fructose (and related sugars)-free diet can prevent the
potentially serious manifestations of the disease.
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